Startseite>>Signaling Pathways>> Others>>ARN726

ARN726

Katalog-Nr.GC45386

ARN726 ist ein potenter NAAA (N-AcylethanolaminosÄureamidase)-Inhibitor mit einem IC50 von 0,073 μM.

Products are for research use only. Not for human use. We do not sell to patients.

ARN726 Chemische Struktur

Cas No.: 1628343-77-0

Größe Preis Lagerbestand Menge
1mg
43,00 $
Auf Lager
5mg
161,00 $
Auf Lager
10mg
280,00 $
Auf Lager
25mg
643,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ARN726 is an inhibitor of N-acylethanolamine acid amidase (NAAA; IC50s = 27 and 63 nM for the human and rat enzyme, respectively).1 It is selective for NAAA over fatty acid amide hydrolase (FAAH) and acid ceramidase (IC50s = >100 and 12.5 μM, respectively), as well as a panel of 28 lipid metabolism- and inflammation-related enzymes at 10 μM. ARN726 (1-30 mg/kg) decreases lung myeloperoxidase activity and pleural exudate TNF-α levels in a mouse model of carrageenan-induced lung inflammation. It inhibits NAAA and reverses complete Freund's adjuvant-induced decreases in palmitoyl ethanolamide and oleoyl ethanolamide levels in inflamed paw tissue in a rat model of arthritis.2

References
1. Ribeiro, A., Pontis, S., Mengatto, L., et al. . Chem. Biol. 10, 1838-1846 (2015).
2. Bonezzi, F.T., Sasso, O., Pontis, S., et al. An important role for N-acylethanolamine acid amidase in the complete Freund's adjuvant rat model of arthritis. J. Pharmacol. Exp. Ther. 356(3), 656-663 (2016).

Bewertungen

Review for ARN726

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ARN726

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.